<qa>  What is the main endpoint of the study?Patients will be enrolled in the study by members of GFPC, a French cooperative group on thoracic oncology. The main eligibility criteria are : histologically or cytologically documented inoperable stage IIIA N2 or IIIB NSCLC previously untreated, absence of malignant pleural effusion, performance status PS 1 and patient life expectancy of at least 12 weeks. Induction chemotherapy will comprise two cycles of cisplatin 80mgm2 and docetaxel 75mgm2 given on D1 and D22. Concomitant CT-RT will start on D57. Radiotherapy will occur from D57 until D99 2 Gyday, 5 daysweek, total dose is 66 Gy. Cisplatin 80mgm2 will be given on D57 first day of irradiation and D78. Oral vinorelbine 40 mgm2 will be administered on D57, D64, D78 and D85. The main endpoint is the objective response rate. The tumor response will be assessed first at the end of induction chemotherapy, and again 4 weeks after concurrent CT-RT. Patients who will progress after induction chemotherapy will leave the study. Those with stable disease or a tumor response will receive the CT-RT combination. Tolerability, time until progression, duration of response and proportion of survival at 1, 2 and 3 years represent a secondary endpoints. The study will be achieved according to the French legislation and guidelines for biomedical research involving human subjects. 